Please use this identifier to cite or link to this item:
http://hdl.handle.net/11375/12901
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.advisor | Niles, Len | en_US |
dc.contributor.advisor | Foster, Jane | en_US |
dc.contributor.advisor | Sakic, Boris | en_US |
dc.contributor.author | Sathiyapalan, Arani | en_US |
dc.date.accessioned | 2014-06-18T17:01:11Z | - |
dc.date.available | 2014-06-18T17:01:11Z | - |
dc.date.created | 2013-04-04 | en_US |
dc.date.issued | 2013-04 | en_US |
dc.identifier.other | opendissertations/7748 | en_US |
dc.identifier.other | 8807 | en_US |
dc.identifier.other | 3995577 | en_US |
dc.identifier.uri | http://hdl.handle.net/11375/12901 | - |
dc.description.abstract | <p>Valproic acid (VPA) is clinically utilized as an anti-convulsant and mood stabilizer, though its mechanism of action has not been fully elucidated.<strong> </strong>Evidence suggests an interaction between VPA and the melatonergic system as VPA up-regulated the melatonin MT<sub>1</sub> receptor subtype in rat C6 glioma cells. To determine if the observed effects can translate to an <em>in vivo </em>model, we investigated the effects of chronic VPA administration in a rat model on the expression of MT<sub>1</sub> and MT<sub>2</sub> receptors in the hippocampus. We also investigated the effect of chronic VPA treatment on the expression of the neurotrophic factors BDNF and GDNF in the rat hippocampus and striatum.</p> <p>(1) Animals were separated into two groups with the experimental group receiving VPA (4 mg/mL) for 17 days, and the control receiving vehicle. The hippocampus was dissected and MT<sub>1</sub>, MT<sub>2</sub>, BDNF and GDNF mRNA were analyzed with RT-PCR. (2) Animals were separated into three groups with the first group receiving VPA (4 mg/mL), the second receiving VPA (3 mg/mL) for 16 days, and the control receiving vehicle. MT<sub>2</sub> mRNA in the hippocampal subregions were analyzed with in situ hybridization.</p> <p>VPA induced the expression of MT<sub>1</sub> and MT<sub>2</sub> mRNA in the hippocampus in the experimental group compared to the control group. VPA also increased MT<sub>2</sub> mRNA expression in the subregions of the hippocampus. Additionally, BDNF and GDNF mRNA expression were increased in the VPA treatment group.</p> <p>These findings raise the interesting question of whether the diverse clinical effects of VPA involve an interaction with the melatonergic system.</p> | en_US |
dc.subject | Valproic acid | en_US |
dc.subject | melatonin | en_US |
dc.subject | melatonin receptors | en_US |
dc.subject | GDNF | en_US |
dc.subject | BDNF | en_US |
dc.subject | HDAC inhibitor | en_US |
dc.subject | epigenetic | en_US |
dc.subject | in vivo | en_US |
dc.subject | Molecular and Cellular Neuroscience | en_US |
dc.subject | Neuroscience and Neurobiology | en_US |
dc.subject | Molecular and Cellular Neuroscience | en_US |
dc.title | EFFECTS OF VALPROIC ACID ON EXPRESSION OF THE MELATONIN RECEPTORS MT1 AND MT2, AND THE NEUROTROPHIC FACTORS BDNF AND GDNF IN VIVO | en_US |
dc.type | thesis | en_US |
dc.contributor.department | Medical Sciences (Neuroscience and Behavioral Science) | en_US |
dc.description.degree | Master of Science (MSc) | en_US |
Appears in Collections: | Open Access Dissertations and Theses |
Files in This Item:
File | Size | Format | |
---|---|---|---|
fulltext.pdf | 3.55 MB | Adobe PDF | View/Open |
Items in MacSphere are protected by copyright, with all rights reserved, unless otherwise indicated.